Clinical Trials Directory

Trials / Completed

CompletedNCT02017210

Insulin-sensitive Obesity: Lessons From Longitudinal Data

Insulin-sensitive Obesity: Prospective and Interventional Studies

Status
Completed
Phase
Study type
Observational
Enrollment
57 (actual)
Sponsor
Garvan Institute of Medical Research · Academic / Other
Sex
All
Age
26 Years – 75 Years
Healthy volunteers
Accepted

Summary

People who are overweight and/or obese are at risk of insulin resistance and type 2 diabetes. However, research has shown that some overweight and/or obese individuals remain insulin-sensitive and metabolically healthy despite their unhealthy body weight. The investigators hypothesise that overweight and/or obese people who were deemed insulin-sensitive in previous studies will maintain their insulin sensitivity and metabolic health over time. The investigators also hypothesise that the preservation of insulin sensitivity will be accompanied by key metabolic health markers.

Detailed description

While obesity is a risk factor for metabolic disease, sub cohorts with obesity not complicated by the metabolic syndrome have been described. These so called "metabolically healthy obese" may have reduced risk of type 2 diabetes, cardiovascular disease and all-cause mortality compared with individuals with obesity who present with components of the metabolic syndrome. Longitudinal studies with diabetes and cardiovascular disease risk endpoints reported that individuals with obesity who are metabolically healthy (MHO) held an intermediate health status, such that they were still worse off than the healthy normal-weight individuals. While there have been studies evaluating the stability of the MHO phenotype over time, no study has reported the durability of insulin-sensitivity per se, as measured by the gold-standard hyperinsulinaemic-euglycaemic clamp. In the present study, we aimed to trace the change in insulin resistance/sensitivity, and to uncover predictors of insulin resistance in older age. The secondary aims were to trace the change in body composition, fat distribution and metabolic markers over time in a well-phenotyped cohort studied approximately 5-6 years apart.

Conditions

Timeline

Start date
2013-11-01
Primary completion
2016-02-01
Completion
2016-02-01
First posted
2013-12-20
Last updated
2020-02-24
Results posted
2020-02-24

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT02017210. Inclusion in this directory is not an endorsement.